Trial Profile

Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertussis acellular vaccine (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 11-valent vaccine conjugate; RIX 4414
Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
Focus Pharmacodynamics
Acronyms PA-TRICOMP005
Sponsors GlaxoSmithKline; GSK

Most Recent Events

06 Apr 2022 This trial has been completed in Netherland (End Date: 26 Aug 2012), according to European Clinical Trials Database record.
28 Feb 2018 This trial has been discontinued in Belgium as per European Clinical Trials Database record.
24 Feb 2011 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com